Drug profile · INN
peginesatide
OMONTYS
peginesatide (OMONTYS) is a erythropoietin receptor agonist. Associated with Takeda.
EMA: application withdrawn Blood and blood forming organs (B03) B03XA
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — peginesatide
- Class
- Blood and blood forming organs (B03)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
peginesatide (OMONTYS) is a erythropoietin receptor agonist. Associated with Takeda.
Key facts
INN peginesatide
Brand OMONTYS
Mechanism Erythropoietin receptor agonist
Target Erythropoietin receptor
Therapeutic class Blood and blood forming organs (B03)
ATC code B03XA
Originator Takeda
Mechanism of action
Erythropoietin receptor agonist
Primary target: Erythropoietin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is peginesatide?
peginesatide (OMONTYS) is a erythropoietin receptor agonist. Associated with Takeda.
What is the brand name for peginesatide?
OMONTYS is a marketed brand name for peginesatide. Check FDA Drugs@FDA for the current US label holder and prescribing information.